scholarly journals Survival outcomes associated with completion of adjuvant oxaliplatin‐based chemotherapy for stage III colon cancer: a national population‐based study.

2021 ◽  
Author(s):  
Jemma M. Boyle ◽  
Angela Kuryba ◽  
Thomas E. Cowling ◽  
Jan Meulen ◽  
Nicola S. Fearnhead ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Population Based ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Population Based Study ◽  
National Population ◽  
Stage Iii Colon Cancer

scholarly journals Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Peng Gao ◽  
Xuan-zhang Huang ◽  
Yong-xi Song ◽  
Jing-xu Sun ◽  
Xiao-wan Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

scholarly journals Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study

PLoS ONE ◽  
2018 ◽  
Vol 13 (3) ◽  
pp. e0194415 ◽  
Author(s):  
Karen J. Ortiz-Ortiz ◽  
Guillermo Tortolero-Luna ◽  
Ruth Ríos-Motta ◽  
Alejandro Veintidós-Feliú ◽  
Robert Hunter-Mellado ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Puerto Rico ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study

2016 ◽  
Vol 14 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Christopher M. Booth ◽  
Sulaiman Nanji ◽  
Xuejiao Wei ◽  
Yingwei Peng ◽  
James J. Biagi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008

2012 ◽  
Vol 52 (5) ◽  
pp. 941-949 ◽  
Author(s):  
Colette B. M. van den Broek ◽  
Esther Bastiaannet ◽  
Jan Willem T. Dekker ◽  
Johanneke E. A. Portielje ◽  
Anton J. M. de Craen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Time Trends ◽  
Large Population ◽  
Relative Survival ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer ◽  
Chemotherapy Administration

scholarly journals Decreasing Use of Chemotherapy in Older Patients With Stage III Colon Cancer Irrespective of Comorbidities

2019 ◽  
Vol 17 (9) ◽  
pp. 1089-1099 ◽  
Author(s):  
Viola Walter ◽  
Daniel Boakye ◽  
Janick Weberpals ◽  
Lina Jansen ◽  
Walter E. Haefeli ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Elderly Patients ◽  
Old Age ◽  
Population Based ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Patient Interviews ◽  
Chemotherapy Administration ◽  
Hospital Factors ◽  
Chemotherapeutic Treatment

Background: Chemotherapy underuse in elderly patients (aged ≥75 years) with colon cancer has been reported in previous studies. However, these studies were mostly registry-based and limited in their potential to consider underlying reasons of such undertreatment. This study aimed to evaluate patient and hospital determinants of chemotherapeutic treatment in patients with stage III colon cancer, with a particular focus on age and underlying reasons for nontreatment of elderly patients. Methods: A total of 629 patients with stage III colon cancer who were diagnosed in 2003 through 2012 and recruited into a population-based study in the Rhine-Neckar region of Germany were included. Information on sociodemographic and lifestyle factors, comorbidities, and treatment was collected from patient interviews and physicians. Patient (with an emphasis on age) and hospital factors were evaluated for their associations with administration of adjuvant chemotherapy overall and of oxaliplatin specifically using multivariable logistic regression. Results: Administration of chemotherapy decreased from 94% in patients aged 30 to 64 years to 51% in those aged ≥75 years. A very strong decline in chemotherapy use with age persisted even after comprehensive adjustment for multiple patient factors—including comorbidities—and hospital factors and was also seen among patients without any major comorbidities. Between 2005 and 2008, and 2009 and 2012, chemotherapy administration in patients aged ≥75 years decreased from 60% to 41%. Among chemotherapy recipients, old age was also strongly associated with higher odds of nonadministration of oxaliplatin. The 2 most commonly reported reasons for chemotherapy nonreceipt among the study population were patient refusal (30%) and old age (24%). Conclusions: Age was the strongest predictor of chemotherapy underuse, irrespective of comorbidities and even in patients without comorbidities. Such underuse due just to older age in otherwise healthy patients deserves increased attention in clinical practice to ensure that elderly patients also get the best possible care. Patients’ refusal as the most frequent reason for chemotherapy nonreceipt also warrants further investigation to exclude misinformation as underlying cause.

scholarly journals Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study

2020 ◽  
Vol 18 (9) ◽  
pp. 1230-1237 ◽  
Author(s):  
Seyed M. Qaderi ◽  
Paul W. Dickman ◽  
Johannes H.W. de Wilt ◽  
Rob H.A. Verhoeven
Keyword(s):  
Rectal Cancer ◽  
Colon Cancer ◽  
Population Based ◽  
Stage I ◽  
Stage Iii ◽  
Disease Stage ◽  
Conditional Survival ◽  
Population Based Study ◽  
Pathologic Stage ◽  
Number Of Patients

Background: The increasing number of colorectal cancer (CRC) survivors need survival estimates that account for the time already survived. The aim of this population-based study was to determine conditional survival, cure proportions, and time-to-cure (TTC) of patients with colon or rectal cancer. Materials and Methods: All patients with pathologic stage I–III CRC treated with endoscopy or surgery, diagnosed and registered in the Netherlands Cancer Registry between 1995 and 2016, and aged 18 to 99 years were included. Conditional survival was calculated for those diagnosed before and after 2007. Cure proportions were calculated using flexible parametric models. Results: A total of 175,384 patients with pathologic stage I (25%), II (38%), or III disease (37%) were included. Conditional 5-year survival of patients with stage I, II, and III colon cancer having survived 5 years was 98%, 94%, and 92%, respectively. For patients with stage I–III rectal cancer, this was 96%, 89%, and 85%, respectively. Statistical cure in patients with colon cancer was reached directly after diagnosis (stage I) to 6 years (stage III) after diagnosis depending on age, sex, and disease stage. Patients with rectal cancer reached cure 0.5 years after diagnosis (stage I) to 9 years after diagnosis (stage III). In 1995, approximately 42% to 46% of patients with stage III colon or rectal cancer, respectively, were considered cured, whereas in 2016 this percentage increased to 73% to 78%, respectively. Conclusions: The number of patients with CRC reaching cure has increased substantially over the years. This study’s results provide valuable insights into trends of CRC patient survival and are important for patients, clinicians, and policymakers.

Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3598-3598
Author(s):  
Jun Seok Park ◽  
Soo Yeun Park ◽  
Gyu-Seog Choi ◽  
Hye Jin Kim ◽  
Jong Gwang Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Surgical Complication ◽  
Phase Iii ◽  
Stage Iii ◽  
Survival Outcomes ◽  
Stage Iii Colon Cancer

3598 Background: Adjuvant chemotherapy (AC) is recommended to commence within 8 weeks since after surgical resection of stage II or III colon cancer. Results of many retrospective studies showed inferior survival outcomes following delay of AC delay. Moreover, preclinical studies showed that the progression of disseminated cancer cells is profound during the postoperative period. This study is the first prospective trial to evaluate early (≤ 14 days postoperative) AC for patients (pts) with stage III colon cancer. Methods: This study is a prospective, multicenter, randomized phase III trial. Pts with pathological stage III colon cancer were enrolled and randomized 1:1 to early AC (starting AC ≤ 14 days after surgery) or conventional AC (starting AC > 14 days after surgery). Pts were recommended to receive 12 cycles of FOLFOX-6 for AC. The primary endpoint was disease-free survival. The secondary endpoints were overall survival, adverse events, surgical complication during AC, and patient-reported outcomes (quality of life) during 1 year after surgery. Herein, safety data, chemotherapy delivery, and quality of life are presented. Results: This study randomized 443 pts either early AC arm (221pts) or early AC arm (222 pts) to the during September 2011 to March 2020. 380 pts who received at least one cycle of FOLFOX-6 were included in the safety analysis (192 and 188 in the early and conventional AC arms, respectively). The baseline characteristics of the two groups were well-balanced except for the interval from the surgery to the initial AC. The early and conventional AC arms started their first chemotherapy at median of 13 (4-43 days) and 29 (17-53 days) after surgery (p < 0.001), respectively. No significant differences were seen in the median chemotherapy cycles, AC completion, and relative oxaliplatin dose intensity between groups. AC Completion without any change of dose or schedule delay was seen in 18% and 20% in early and conventional AC arms respectively, while dose reduction or delay was 65% and 61%, respectively. Toxicities of grade 3 or more were seen in 28% in both groups. One patient in the early AC arm underwent an emergent operation for anastomotic leakage on the second day of 5-fluorouracil infusion (postoperative day 14). However, the surgical complication was not seen in any other patient. The scores of the European Organization for Research and Treatment of Cancer Quality of Life core 30 questionnaire were similar in both arms at baseline (before starting AC), and 1 month, 3 months, 6 months, and 12 months after surgery. Conclusions: Early AC was safe and did not increase either chemotherapy-related adverse events or surgery-related complications during treatment. Moreover early AC did not reduce the quality of life of the pts during 1 year after surgery. This study continues to follow-up the patients for survival outcomes. Clinical trial information: NCT01460589.

Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 4014-4014 ◽  
Author(s):  
I. H. Zuckerman ◽  
A. J. Davidoff ◽  
E. Onukwugha ◽  
N. Pandya ◽  
J. F. Gardner ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Survival Benefit ◽  
Population Based ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Effect Of Age
Sign in / Sign up

Export Citation Format

Share Document